Fate Therapeutics (STU:F6T) Moat Score: 4/10 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:F6T Fate Therapeutics Inc STU:F6T
39 GF Score
Price €2.21
GF Value €0.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Moat Score?

Fate Therapeutics STU:F6T +1.57% 39 Moat Score is 4 as of Aug. 16, 2026. GuruFocus rates STU:F6T with a GF Score™ of 39/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,389 Biotechnology companies, Fate Therapeutics ranks better than 88.77% on this metric.

Fate Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Fate Therapeutics has Narrow Moat: Fate Therapeutics Inc has valuable intellectual property and strong R&D capabilities in the biotech sector. However, the company faces significant competition and regulatory challenges, limiting its ability to establish a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fate Therapeutics might have Narrow Moat - Discernible but modest moat.

Fate Therapeutics  (STU:F6T) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fate Therapeutics Moat Score Related Terms

STU:F6T vs IMRX, NWBO, FHTX: Moat Score Comparison

For the Biotechnology subindustry, Fate Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fate Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Moat Score falls into.


STU:F6T
39GF Score
Fate Therapeutics Inc STU:F6T
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Fate Therapeutics (STU:F6T) has a Moat Score of 4 as of Aug. 16, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fate Therapeutics ranks #156 out of 1389 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Fate Therapeutics' Moat Score too high?
Fate Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Fate Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Fate Therapeutics ranks #156 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fate Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Moat Score compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #156 out of 1389 companies for Moat Score. This places Fate Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Fate Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,389 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (STU:F6T) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €2.21 — trading 244.7% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Fate Therapeutics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fate Therapeutics (STU:F6T), the current Moat Score is 4 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fate Therapeutics (STU:F6T) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of €2.21 is trading 244.7% above its estimated GF Value™ of €0.64. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:F6T:

  • Moat Score: 4
  • GF Value™: €0.64 vs. price of €2.21 (244.7% above fair value)
  • GF Score™: 39/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1389)

No single metric tells the full story. See the STU:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fate Therapeutics Business Description

Other Exchanges FATE:USA
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
39GF Score

Get the complete analysis for STU:F6T

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21
Price
€0.64
GF Value